Related Experiment Videos
Intravenous nicardipine in hypertensive preterm infants
J B Gouyon1, B Geneste, D S Semama
1Service de Pédiatrie 2, Hôpital d'Enfants, Dijon, France.
Summary
Intravenous nicardipine effectively lowered blood pressure in preterm infants with hypertension. This calcium channel blocker showed significant results without causing adverse effects, suggesting it as a primary treatment option.
Area of Science:
- Neonatal Medicine
- Pediatric Cardiology
- Pharmacology
Background:
- Systemic hypertension is a serious concern in preterm infants.
- Causes include renal artery thrombosis, bronchopulmonary dysplasia management, and unexplained factors.
- Effective and safe antihypertensive treatments are crucial for this vulnerable population.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous nicardipine for treating systemic hypertension in preterm infants.
- To determine the impact of nicardipine on systolic and diastolic blood pressure.
- To assess potential clinical side effects associated with nicardipine administration.
Main Methods:
- Eight preterm infants with systemic hypertension received intravenous nicardipine.
- Doses ranged from 0.5 to 2.0 micrograms/kg/min, administered for 3 to 36 days.
- Blood pressure was monitored to assess treatment response.
Main Results:
- Significant reductions in systolic blood pressure were observed at 12 and 24 hours (-17% and -21%, respectively).
- Diastolic blood pressure significantly decreased after 24 hours (-22%).
- Blood pressure reductions remained significant throughout the treatment period, with no reported hypotension or adverse events.
Conclusions:
- Intravenous nicardipine is an effective treatment for hypertension in preterm infants.
- The drug demonstrated significant blood pressure-lowering effects with a favorable safety profile.
- Nicardipine is proposed as a potential first-line therapy for hypertensive preterm neonates.